Laboratory Corporation Of America ( (LH) ) has released its Q1 earnings. Here is a breakdown of the information Laboratory Corporation Of America presented to its investors.
Laboratory Corporation of America, commonly known as Labcorp, is a global leader in laboratory services, providing diagnostics and drug development support to healthcare providers and pharmaceutical companies worldwide. The company is known for its innovative approach and extensive test menu, serving clients in approximately 100 countries.
In its first-quarter earnings report for 2025, Labcorp reported a revenue increase to $3.35 billion, up from $3.18 billion in the same period last year. Despite a slight decrease in diluted earnings per share (EPS) from $2.69 to $2.52, the adjusted EPS rose to $3.84 from $3.68, reflecting the company’s strong operational performance.
Key highlights from the report include Labcorp’s strategic collaborations and acquisitions aimed at expanding its testing capabilities, particularly in oncology and neurology. The company introduced new tests, such as the Labcorp Plasma Complete for cancer and the pTau-217/Beta Amyloid 42 Ratio test for Alzheimer’s disease diagnosis. Additionally, Labcorp’s Diagnostics Laboratories segment saw a 6.0% revenue increase, driven by organic growth and acquisitions.
Labcorp’s management remains optimistic about the future, reaffirming its revenue and free cash flow guidance while slightly raising the midpoint of its adjusted EPS guidance. The company continues to focus on expanding its test offerings and enhancing its partnerships to drive growth in 2025 and beyond.